Mylan NV (MYL.OQ)
35.53USD
20 Jul 2018
$-0.11 (-0.31%)
$35.64
$35.61
$36.02
$35.40
1,426,581
1,407,421
$47.81
$29.44
Tue, Jul 17 2018
Mylan signs U.S. license deal on Humira with AbbVie
AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.
Mylan signs U.S. license deal on Humira with AbbVie
July 17 AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.
BUZZ-India's Dr.Reddy's Laboratories plunges; Indivior wins preliminary injunction against co
** Dr.Reddy's Laboratories Ltd falls as much as 10.8 pct to a five-week low of 2,069.95 rupees
BUZZ-India's Dr.Reddy's rises on US drug hopes; UK rival Indivior cuts guidance
** Dr.Reddy's Laboratories Ltd rise as much as 3.8 pct to 2,387.65 rupees, its highest in 3 weeks
Indivior says 2018 profit to fall short after U.S. market hit
British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.
Indivior gets breather after court extends order blocking generic rival
Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.
Indivior gets breather after court extends order blocking generic rival
Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.
FDA finds deficiencies in Mylan's generic Advair; shares fall
Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.
UPDATE 2-FDA finds deficiencies in Mylan's generic Advair; shares fall
* Shares fall 4.5 pct after market (Adds analyst comment; updates shares)
FDA finds deficiencies in Mylan's generic Advair
June 13 U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.